http://www.zibb.com/all/theme/cq/OXiGENE+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 24 Nov 2009 07:05:31 GMTTue, 24 Nov 2009 07:05:31 GMT608831http://www.zibb.com/all/theme/cq/OXiGENE+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.oxigene.com/copyright.aspGeneral Guidelines OXiGENE will use reasonable efforts to include accurate and up-to-date information on www.oxigene.com, but OXiGENE makes no warranties or representations as to the information's appropriateness for a particular purpose.http://www.oxigene.com/copyright.aspOXiGENE Incorporatedhttp://www.biz-lib.com/ZEB67258.htmlOver 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.http://www.biz-lib.com/ZEB67258.htmlOXiGENE Incorporatedhttp://www.evaluatepharma.com/CoInfo/CoInfo-OXGN.htmEvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.http://www.evaluatepharma.com/CoInfo/CoInfo-OXGN.htmOXiGENE Incorporatedhttp://www.apria.com/resources/1,2725,494-857527,00.htmlSymphony ViDA was established by OXiGENE and Symphony to develop OXi4503, OXiGENE's dual-mechanism, second-generation vascular disrupting agent (VDA), and topical-route ZYBRESTAT for ophthalmology.http://www.apria.com/resources/1,2725,494-857527,00.htmlOXiGENE Incorporatedhttp://www.quotelinks.com/companies/oxgn.htmlStock quotes, news and charts for OXiGENE, Inc. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/oxgn.htmlOXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=3901Clinical Investigator Reports that CA4P in Combination with Carboplatin and/or Paclitaxel Indicates Anti-tumor Activity and No Unexpected Toxicity Waltham, Mass., May 13, 2005 - OXiGENE, Inc.http://www.pharmacychoice.com/News/article.cfm?Article_ID=3901OXiGENE Incorporatedhttp://www.jonesday.com/experience/experience_detail.aspx?exID=S13820Summary: Jones Day advised Symphony Capital Partners, L.P., and its co-investors in connection with a series of transactions with OXiGENE, Inc. to provide up to $40 million to further advance OXiGENE's pipeline of vascular disrupting agent drug candidates for cancer and eye diseases.http://www.jonesday.com/experience/experience_detail.aspx?exID=S13820OXiGENE Incorporatedhttp://www.biospace.com/news_story.aspx?StoryID=41159&full=1WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced it has completed a Phase II Study in patients with advanced imageable malignancies.http://www.biospace.com/news_story.aspx?StoryID=41159&full=1OXiGENE Incorporatedhttp://www.mintz.com/news/pressreleases.cfm?p=247&printerfriendly=trueBoston -- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented OXiGENE, Inc. in its recent private investment in public equity (PIPE) transaction pursuant to which OXiGENE raised $15 million. The Watertown-based biotechnology company sold 1.http://www.mintz.com/news/pressreleases.cfm?p=247&printerfriendly=trueOXiGENE Incorporatedhttp://www.newsrx.com/newsletters/Pharma-Business-Week/2007-03-12/350312200732PB.htmlMarch 12th, 2007 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the Company as Senior Vice President and Chief Business Officer. Mr.http://www.newsrx.com/newsletters/Pharma-Business-Week/2007-03-12/350312200732PB.htmlOXiGENE Incorporatedhttp://www.meds.com/archive/mol-cancer/1998/11/msg02096.htmlOXiGENE Initiates Phase I Studies of Combretastatin Tumor Vascular Targeting Agent Attacks Cancer-Specific Blood Vessels Formed by Angiogenesis BOSTON, Nov. 11 /PRNewswire/ -- Addressing the ABN AMRO Health Care Conference in New York, Bjorn Nordenvall, M.D., Ph.D.http://www.meds.com/archive/mol-cancer/1998/11/msg02096.htmlOXiGENE Incorporatedhttp://www.buyandhold.com/StockMgr?request=display.content&symbol=OXGN&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=OXGNCopyright © 2007 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by ComStock, an Interactive Data Company and subject to the Terms of Use.http://www.buyandhold.com/StockMgr?request=display.content&symbol=OXGN&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=OXGNOXiGENE Incorporatedhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=109763&category=1Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=109763&category=1OXiGENE Incorporatedhttp://www.oxigene.com/siteusage.aspOXiGENE, Inc. is pleased to provide you with the materials on our web site for informational purposes. Please carefully read the following paragraphs. By using our web site, you agree to the terms described below. If you do not agree to the terms discussed here, you should exit this web site now.http://www.oxigene.com/siteusage.aspOXiGENE Incorporatedhttp://www.oxigene.com/investor/home.aspOXiGENE is headquartered in Waltham, Massachusetts. By maintaining operations in key biomedical research centers in the U.S. and Europe, we have been able to develop strong collaborative relationships with leading universities and research institutes on both continents.http://www.oxigene.com/investor/home.aspOXiGENE Incorporatedhttp://www.oxigene.com/vascular/vascular.aspZYBRESTAT (combretastatin-A4 phosphate / CA4P) is OXiGENE's lead vascular disrupting agent (VDA) product candidate, which is currently being evaluated in multiple clinical trials as a treatment for various solid tumors.http://www.oxigene.com/vascular/vascular.aspOXiGENE Incorporatedhttp://www.oxigene.com/investor/governance.aspOXiGENE's commitment to ethical business practices is reflected in the committee structure, charters and code of conduct adopted by our Board of Directors. As a resource we have provided these documents for your reference.http://www.oxigene.com/investor/governance.aspOXiGENE Incorporatedhttp://www.oxigene.com/collab/collab.aspOXiGENE continually searches the market for new ideas and technologies that meet the Company's criteria for product development and align with our core strategy to develop a family of compounds applicaple to oncology and ophthamology.http://www.oxigene.com/collab/collab.aspOXiGENE Incorporatedhttp://www.oxigene.com/investor/factsheet.aspAbout OXiGENE OXiGENE is a biopharmaceutical company whose mission is finding (via discovery or in-licensing) and developing new and improved therapeutics that address the significant unmet medical needs of patients with cancer and eye disease.http://www.oxigene.com/investor/factsheet.aspOXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=39707OXiGENE: * Outlines goals and priorities going forward * Describes newly observed safety characteristics and potentially promising new combination alternatives for its compounds * Sets strategic pathway for its clinical development Waltham, MA, -- October 25, 2006 -- OXiGENE, Inc.http://www.pharmacychoice.com/News/article.cfm?Article_ID=39707OXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=58239WALTHAM, MA--May 31, 2007--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the Company has reached agreement with the U.S.http://www.pharmacychoice.com/News/article.cfm?Article_ID=58239OXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=36014Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213) WALTHAM, MA.--(BUSINESS WIRE)--September 12, 2006--OXiGENE, Inc.http://www.pharmacychoice.com/News/article.cfm?Article_ID=36014OXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=24886BIOWIRE2K WALTHAM, Mass.--(BUSINESS WIRE)--March 29, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced the issuance of U.S. Patent No.http://www.pharmacychoice.com/News/article.cfm?Article_ID=24886OXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=4033Some of these preliminary findings are contained in an abstract titled "CA4P plus Radiotherapy: Clinical Results" published for attendees of the 2005 American Society of Clinical Oncology Annual Meeting taking place May 13th-17th in Orlando, Florida.http://www.pharmacychoice.com/News/article.cfm?Article_ID=4033OXiGENE Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=44796WALTHAM, Mass.--(BUSINESS WIRE) - December 27, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced it has completed a Phase II Study in patients with advanced imageable malignancies.http://www.pharmacychoice.com/News/article.cfm?Article_ID=44796OXiGENE Incorporated